RecruitingPhase 1Phase 2NCT07564401

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

A Phase I/II Open-label Study of DJI136, a DLL3-targeted CAR-T Therapy, in Adult Patients With ES-SCLC

Sponsor

Novartis Pharmaceuticals

Enrollment

80 participants

Start Date

Jun 16, 2026

Study Type

INTERVENTIONAL

Conditions

Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Summary

This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DJI136 for people with extensive-stage small cell lung cancer (es-sclc). The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.